Pharmaceutical composition and application thereof in preparation of medicine for preventing and treating red bottom of babylonia lutosa in seedling raising process

Abstract

The invention discloses a pharmaceutical composition. The pharmaceutical composition comprises an agent A and an agent B, the agent A comprises vibrio parahaemolyticus bacteriophage, vibrio harveyi bacteriophage, vibrio alginolyticus bacteriophage and bdellovibrio bacteriovorus; the agent B is prepared from bacitracin, brevibacin, polymyxin and nisin. The method can effectively restrain and solve the red bottom phenomenon of the pond bottom in the babylonia breeding process, and the babylonia breeding success rate is increased.

Description

Technical Field

[0001] The invention belongs to the technical field of snail cultivation, and more specifically, relates to a pharmaceutical composition and an application thereof in preparing a medicine for preventing and controlling red bottom in the process of raising seedlings of Babylonia snails. Background Art

[0002] Babylonia conch is one of the important marine biological resources. Due to its high economic value, the artificial cultivation of babylonia conch has developed rapidly. At present, the main artificially cultivated babylonia conch species in my country are Babylonia areolata, Babylonia Lani, Babylonia lutosa and Babylonia formosae. Due to market demand, the scale and area of ​​babylonia conch cultivation have been expanding year by year, and it has become one of the main species of marine aquaculture in the south.

[0003] However, in recent years, bacterial and fungal diseases have frequently occurred during large-scale and high-density intensive seedling cultivation, which has seriously restricted the development of the factory-based farming industry of Babylonia areolata. Especially in the middle and late stages of Babylonia snail seedling cultivation, multiple red circles composed of harmful fungi and bacterial colonies often appear at the bottom of the nursery pond, which is called the "red bottom" phenomenon. The "red bottom" phenomenon greatly affects the survival rate of Babylonia snail seedlings and the subsequent metamorphosis process of Babylonia snail seedlings. The planktonic larvae of Babylonia snails die as soon as they fall to the bottom during metamorphosis, with a mortality rate of more than 95%.

[0004] Regarding the occurrence of the "red bottom" phenomenon during the breeding process of Dongfeng snails, "Research Progress in Breeding, Nutrition and Disease of Spotted Dongfeng Snails, Chen Meng, College of Animal Science and Technology of Zhongkai University of Agriculture and Engineering" disclosed that the pathogens of Dongfeng snail diseases that have been identified so far are mainly divided into two categories; one is bacterial diseases, including swollen snout disease caused by variants of Vibrio anguillarum, snout edema disease caused by Vibrio harveyi, acute mortality disease (also known as flip back disease) caused by Vibrio harveyi or Vibrio tarveyi, Vibrio outbreak disease, foot swelling, impetigo, respiratory tract inflammation, etc.; the second is parasitic diseases, including ciliate disease caused by aggregate worms in the planktonic stage, shell-meat separation disease (also known as shelling disease) caused by copepods besieging young / immature snails, and monosporia disease caused by variants of monosporidia in the grow-out stage.

[0005] However, there is currently no suitable treatment for this "red bottom" phenomenon. Finding a safer and more environmentally friendly disease prevention and control method, providing a product and method that can effectively prevent and control the red bottom during the Dongfeng snail seedling cultivation process and improve the success rate of Dongfeng snail seedling cultivation has become a technical problem that needs to be solved urgently. Summary of the invention

[0006] In view of the above-mentioned existing technical problems, the primary purpose of the present invention is to provide a pharmaceutical composition, which is used in combination with agent A and agent B, and can effectively inhibit and solve the "red bottom" phenomenon that appears at the bottom of the pond during the Dongfeng snail seedling cultivation process, thereby improving the success rate of Dongfeng snail seedling cultivation.

[0007] The second object of the present invention is to provide a method for preparing the pharmaceutical composition.

[0008] The third object of the present invention is to provide a pharmaceutical composition for use in preparing a drug for increasing the amount of Babylonia snail seedlings or the success rate of seedling cultivation.

[0009] The fourth object of the present invention is to provide a pharmaceutical composition for use in preparing a drug for preventing and / or treating red bottom in the process of raising seedlings of Babylonia snails.

[0010] The fifth object of the present invention is to provide a method for raising and cultivating baby cones.

[0011] In order to achieve the above object, the present invention is implemented by the following technical solutions:

[0012] A pharmaceutical composition comprises an agent A and an agent B; the agent A comprises a Vibrio parahaemolyticus phage, a Vibrio harveyi phage, a Vibrio alginolyticus phage and a Bdellovibrio phage; the agent B comprises bacitracin, gramicidin, polymyxin and nisin.

[0013] Furthermore, the pharmaceutical composition also includes Agent C; the Agent C includes Bacillus subtilis, Bacillus velez, Bacillus licheniformis, Bacillus pumilus, Bacillus coagulans, Bacillus megaterium and Bacillus circulans.

[0014] In the present invention, agent A grows and reproduces in the pool, can cause the lysis of pathogenic bacteria, reduce the density of pathogenic bacteria, thereby reducing or avoiding the chance of pathogenic bacteria infection or disease, and achieves the purpose of treating and preventing diseases. Under the combined action of multiple bacteriophages, the prevention and treatment effect is better.

[0015] Furthermore, the B agents are all polypeptide substances, which have broad-spectrum antibacterial and bactericidal effects. First, the outer membrane of sensitive bacteria is affected. The amino groups of the annular polypeptide part and the divalent cation binding points of the bacterial outer membrane lipopolysaccharide produce electrostatic interactions, which destroy the integrity of the outer membrane, and the fatty acid part of the drug is able to penetrate the outer membrane, thereby increasing the permeability of the plasma membrane, causing the escape of small molecules such as phosphates and nucleosides in the cytoplasm, causing cell dysfunction and even death. The combination of multiple peptides of the present invention can enhance the effect of medication.

[0016] Furthermore, all C agents are spore-forming bacteria, and their functions include: ① Competition, which has more advantages in spatial site competition, and can rapidly and massively multiply and colonize in the water of the nursery pond, effectively preventing the reproduction of pathogenic microorganisms, interfering with the infection of pathogenic microorganisms on planktonic larvae, and destroying the colonization of pathogenic microorganisms on the larvae, thereby achieving the effect of inhibiting bacteria and controlling diseases. ② Melting bacteria, which can be adsorbed on the hyphae of pathogenic fungi and grow together with the hyphae. During the growth process, lytic substances will be produced, thereby dissolving the mycelium. Generally, it will cause the hyphae to break, disintegrate or the cytoplasm to dissolve; or secondary metabolites will dissolve the cell wall of the pathogenic spores, causing cell wall perforation and deformity. ③ Produce antibacterial substances, producing antibiotic substances that can inhibit the growth of bacteria, viruses, fungi and pathogens.

[0017] The present invention can more effectively inhibit and solve the "red bottom" phenomenon that occurs at the bottom of the pond during the breeding process of baby snails, and the problem that baby snails' planktonic larvae metamorphose and fall to the bottom and die, and can significantly improve the success rate of baby snail breeding and increase the amount of baby snails. The pharmaceutical composition provided by the present invention has the advantage of low safety and can be promoted on a large scale.

[0018] Preferably, the mass ratio of the Vibrio parahaemolyticus phage, the Vibrio harveyi phage, the Vibrio alginolyticus phage and the Bdellovibrio phage is 1-2:1-2:1-2:3-5.

[0019] Preferably, the mass ratio of bacitracin, gramicidin, polymyxin and nisin is 1:2 to 4:1 to 3:1.

[0020] Preferably, the mass ratio of the Bacillus subtilis, Bacillus velezensis, Bacillus licheniformis, Bacillus pumilus, Bacillus coagulans, Bacillus megaterium and Bacillus circulans is 3-4:0.8-1.5:3-4:2-3:1.5-2:1-2:1.

[0021] Preferably, the mass ratio of the agent A, the agent B and the agent C is 1-3:2-4:5-8.

[0022] Preferably, the pharmaceutical composition further comprises a carbon source and / or a nitrogen source.

[0023] Preferably, the mass ratio of the carbon source to the nitrogen source is 1-2:1-1.5.

[0024] Preferably, the mass ratio of the total amount of agent A, agent B and agent C to the synergist is 4 to 14: 1. More preferably, the mass ratio is 8 to 12: 1; further preferably, the mass ratio is 10: 1.

[0025] Preferably, the carbon source is selected from one or more of bicarbonate, glucose or acetate. More specifically, the bicarbonate includes but is not limited to sodium bicarbonate, etc.; the acetate includes but is not limited to sodium acetate, etc.

[0026] Preferably, the nitrogen source is selected from one or more of ammonia water, ammonium salts, nitrates or urea. More specifically, the ammonium salts include but are not limited to ammonium sulfate, ammonium chloride and the like.

[0027] Furthermore, the present invention claims a method for preparing a pharmaceutical composition, comprising the following steps:

[0028] (1) mixing Vibrio parahaemolyticus phage, Vibrio harveyi phage, Vibrio alginolyticus phage, and Bdellovibrio phage to prepare agent A;

[0029] (2) mixing bacitracin, gramicidin, polymyxin and nisin to prepare agent B;

[0030] (3) Bacillus subtilis, Bacillus velezensis, Bacillus licheniformis, Bacillus pumilus, Bacillus coagulans, Bacillus megaterium, and Bacillus circulans are mixed to prepare Agent C; more specifically, the temperature of the sterile environment is 25 to 30°C.

[0031] (4) mixing the carbon source and the nitrogen source in proportion to prepare a synergist;

[0032] (5) Mixing Agent A, Agent B, Agent C and a synergist to prepare a pharmaceutical composition.

[0033] Preferably, in step (1), mixing is carried out under sterile conditions at room temperature.

[0034] Preferably, in step (2), mixing is carried out under sterile conditions at room temperature.

[0035] Preferably, in step (3), mixing is carried out under sterile conditions.

[0036] Preferably, in step (4), mixing is carried out under normal temperature and pressure.

[0037] Furthermore, the present invention seeks to protect the use of the pharmaceutical composition in the preparation of a drug for increasing the amount of Babylonia snail seedlings or the success rate of seedling cultivation.

[0038] Furthermore, the present invention seeks to protect the use of the pharmaceutical composition in the preparation of a drug for preventing and / or treating red bottom in the process of raising seedlings of Babylonia snails.

[0039] Specifically, in the present invention, the success rate of raising baby snails refers to: the ratio of the amount of baby snails to the total number of planktonic larvae of baby snails.

[0040] Specifically, in the present invention, the red bottom refers to: a red circle composed of multiple harmful fungi and / or bacterial colonies appearing at the bottom of the Babylonia snail breeding pond.

[0041] Furthermore, the present invention seeks to protect a method for cultivating seedlings of Babylonia snails, which uses the above-mentioned pharmaceutical composition to cultivate seedlings of Babylonia snails.

[0042] Preferably, during the seedling cultivation process, the water temperature is maintained at 20-30°C, the dissolved oxygen is 5-7 mg / L, and the pH is 8.2-8.5.

[0043] In some specific embodiments, the above-mentioned pharmaceutical composition can be used for preventive seedling cultivation immediately after the hatching of the Dongfeng snail egg sacs, and can also be used for therapeutic seedling cultivation of the Dongfeng snail planktonic larvae that have already shown the red bottom phenomenon.

[0044] In some embodiments, when the prevention is performed, the dosage of the pharmaceutical composition is 0.5 to 1.5 ppm with a cycle of 1 to 5 days. More preferably, the dosage of the pharmaceutical composition is 0.6 to 1.2 ppm.

[0045] In some embodiments, when the treatment is performed, the pharmaceutical composition is used once a day for 2 to 4 consecutive days, with a dosage of 3 to 15 g / m 3 More preferably, the dosage is 5 to 10 g / m 3 .

[0046] Specifically, the babylonia is of the genus Babylonia (Babylonia), including but not limited to Babylonia areolata, Babylonia lutosa, Babylonia formosae, etc.

[0047] Compared with the prior art, the present invention has the following beneficial effects:

[0048] The present invention provides a pharmaceutical composition, which can more effectively inhibit and solve the red bottom phenomenon that occurs at the bottom of a pond during the breeding process of baby snails, and the problem that baby snail larvae metamorphose and fall to the bottom and die; it can significantly reduce the mortality of baby snail larvae after infection, improve the body immunity of snail seedlings, the amount of baby snail seedlings and the success rate of breeding. The pharmaceutical composition provided by the present invention has the advantages of low safety and can be promoted on a large scale. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 This is a schematic diagram of Example 4 in which the water level of the nursery pond is lowered to reveal a red bottom and some of the Babylonia snail larvae sink to the bottom and die.

[0050] Figure 2Schematic diagram of the nursery pond after successful seedling cultivation in Example 4 to cure the red bottom phenomenon. DETAILED DESCRIPTION

[0051] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0052] The phrase "early veliger larval stage" refers to the developmental period when two residual yolk masses are clearly visible in the body of the Babylonia snail larvae, and there are two oval veligers that are symmetrical on both sides and have densely ciliated edges.

[0053] The phrase "mid-veliger larvae" means that the yolk mass of the Babylonia snail larvae disappears, and it has distinct features such as eyes, forelegs, primary shells, and a pair of antennae.

[0054] The phrase "late veliger larvae" means that the larvae of the Dongfeng snail have a proboscis on their heads, water tubes, clearly differentiated gill filaments, and 1 to 2 rows of reddish-brown pigment spots on the whorls.

[0055] Example 1 A pharmaceutical composition

[0056] (1) Under normal temperature and aseptic conditions, Vibrio parahaemolyticus phage A3S, Vibrio harveyi phage Viha10, Vibrio alginolyticus phage HH109, ​​and Bdellovibrio phage NA7 (all of the above strains are from Shanghai Xinweilai Biotechnology Co., Ltd.) are mixed in a mass ratio of 1:1:1:4 to prepare Agent A;

[0057] (2) under normal temperature and aseptic conditions, bacitracin, gramicidin, polymyxin and nisin were mixed in a mass ratio of 1:4:3:1 to prepare agent B;

[0058] (3) Under sterile environmental conditions at 25-30° C., Bacillus subtilis BS-01, Bacillus Velezii YFI-4, Bacillus licheniformis JHD-Z2, Bacillus pumilus DS-3, Bacillus coagulans NR372, Bacillus megaterium NCT-2, and Bacillus circulans L38 (all of the above strains are from the China General Microbiological Culture Collection Center) are mixed in a mass ratio of 4:1:4:3:2:1.5:1 to prepare Agent C;

[0059] (4) At room temperature and pressure, sodium bicarbonate and ammonium chloride are mixed in a mass ratio of 2:1 to obtain an auxiliary agent;

[0060] (5) At room temperature and pressure, Agent A, Agent B and Agent C are mixed at a mass ratio of 2:2:7 under aseptic conditions at room temperature, and then the mixture and the auxiliary agent are mixed at a mass ratio of 10:1 under aseptic conditions at room temperature to prepare a pharmaceutical composition.

[0061] Example 2 A pharmaceutical composition

[0062] The difference between this embodiment and embodiment 1 is that:

[0063] Agent A is a mixture of Vibrio parahaemolyticus phage, Vibrio harveyi phage, Vibrio alginolyticus phage, and Bdellovibrio phage in a mass ratio of 2:2:1:3;

[0064] Agent B is a mixture of bacitracin, gramicidin, polymyxin and nisin in the ratio of 1:3:2:1.

[0065] Agent C is a mixture of Bacillus subtilis, Bacillus velezensis, Bacillus licheniformis, Bacillus brevis, Bacillus coagulans, Bacillus megaterium and Bacillus circulans in a mass ratio of 3:1:3:2:2:2:1.

[0066] Example 3 A pharmaceutical composition

[0067] The difference between this embodiment and embodiment 1 is that:

[0068] Agent A is a mixture of Vibrio parahaemolyticus phage, Vibrio harveyi phage, Vibrio alginolyticus phage, and Bdellovibrio phage in a mass ratio of 1.5:2:1.5:4;

[0069] Agent B is a mixture of bacitracin, gramicidin, polymyxin and nisin in a mass ratio of 1:4:2.5:1.

[0070] Agent C is a mixture of Bacillus subtilis, Bacillus velezensis, Bacillus licheniformis, Bacillus brevis, Bacillus coagulans, Bacillus megaterium and Bacillus circulans in a mass ratio of 4:1:3.5:2.5:2:1.5:1.

[0071] Example 4 Treatment test of red bottom in the process of raising baby snails

[0072] Purchase egg capsules of Babylonia square-spotted from Wenchang, Hainan, wash the surface attachments and mud with seawater, remove the whitish and reddish infected egg capsules, put them in the hatching basket, and put 4 jin of egg capsules in each nursery pond. The nursery pond is 3m×4m×1m in size, with a water depth of 0.8m. The water temperature is 28℃ when entering the pond. Before hatching, turn the pond over once a day. When hatching is approaching, do not move it anymore, and keep the hatching density at 0.1 / ml.

[0073] During the cultivation period, aeration is carried out continuously. During the early stage of the disc larvae, 1 / 3 of the water is changed every day. During the early stage of the disc larvae, 1 / 2 of the water is changed every day. During the early stage of the disc larvae, 3 / 4 of the water is changed every day. In the early stage, all golden algae are fed. In the middle stage, golden algae are mainly fed, supplemented by Chaetoceros algae. In the later stage, golden algae, Chaetoceros algae, and Platyphyllum are mixed according to the bait situation. The feeding of golden algae is 3,000 / ml per day at the beginning, and gradually increases to 17,000 / ml per day in the later stage; Chaetoceros algae and Platyphyllum are fed as appropriate according to the amount of stomach contents of the planktonic larvae. Feeding is increased from 2 times a day at the beginning to 4 times a day in the later stage. At the same time, spirulina powder is fed as an auxiliary. The feeding amount depends on the actual situation, 2-3 grams / m 3 , feed 2 to 3 times a day.

[0074] On the 10th day of cultivation, the nursery pool was already full of red circles (i.e., a "red bottom" phenomenon appeared, such as Figure 1 As shown), the pharmaceutical composition prepared in Example 1 was prepared at 5 g / m 3 Spray the entire pond (based on the volume of the aquaculture water body), once a day, for 3 consecutive days, and the red circle on the bottom of the pond will disappear (such as Figure 2 shown).

[0075] Example 5 Treatment test of red bottom in the process of raising baby snails

[0076] The difference between this example and example 4 is that the treatment started on day 11, using the pharmaceutical composition prepared in example 2. The dosage, frequency and time of the pharmaceutical composition were the same as those in example 4.

[0077] Example 6 Prevention test of red bottom in the process of raising baby snails

[0078] The difference between this embodiment and embodiment 4 is that as soon as the planktonic larvae of Babylonia snails hatch from the egg capsules, the pharmaceutical composition prepared in embodiment 1 is added once every 2 days, with 1 ppm added each time (based on the volume of the aquaculture water body) until the last day of seedling cultivation.

[0079] Example 7

[0080] The difference between this embodiment and embodiment 4 is that the pharmaceutical composition used contains only agent A and agent B.

[0081] Comparative Example 1

[0082] The difference between this comparative example and Example 4 is that no treatment measures are taken, that is, the pharmaceutical composition prepared in Example 1 is not used.

[0083] Starting from the 11th day, the density of planktonic larvae of Dongfeng snails in the nursery pond water body gradually decreased. By the 13th day, there were almost no planktonic larvae of Dongfeng snails in the nursery pond. The planktonic larvae of Dongfeng snails died and sank to the bottom of the pond, and the nursery cultivation failed.

[0084] Comparative Example 2

[0085] The difference between this comparative example and Example 4 is that the pharmaceutical composition used contains only Agent A and Agent C.

[0086] Comparative Example 3

[0087] The difference between this comparative example and Example 4 is that the pharmaceutical composition used contains only Agent B and Agent C.

[0088] Test Case

[0089] After the hatching of the egg sacs, each nursery pond adopts the five-point sampling method. Water samples are taken from the four corners and the middle of the nursery pond to fill a 250ml measuring cylinder. The number of planktonic larvae of Dongfeng snails in the 250ml measuring cylinder each time is counted, and the average value is converted to obtain the average number of planktonic larvae of Dongfeng snails per 250ml. The average value is multiplied by 4 and 1000 to obtain the number of planktonic larvae of Dongfeng snails per cubic meter of water. The number is then multiplied by the volume of the nursery water body, 9.6 cubic meters, which is the total number of planktonic larvae of Dongfeng snails in the nursery pond.

[0090] Amount of snail seedlings: Randomly take the average count of 50 grams of Dongfeng snail seedlings for 3 times, divide it by 50, and you will get the snail seedling specification (pieces / g). Multiply it by the weight (g) to get the amount of snail seedlings (pieces).

[0091] The calculation formula is as follows:

[0092] The total number of floating larvae of Babylonia sinensis = the sum of the number of larvae in 5 250ml measuring cylinders / 5*4*1000*9.6;

[0093] Snail seedling quantity = average number of 50g Dongfeng snail seedlings in 3 times / 50*number of grams;

[0094] The success rate of seedling cultivation = the number of snail seedlings / the total number of planktonic larvae of Babylonia snails*100%;

[0095] The test data of the above embodiments and comparative examples are shown in Table 1 below.

[0096] Table 1

[0097] Five point average Number of planktonic larvae Snail seedling specifications Weight of snail seedlings Snail seedling quantity Seedling success rate Days the red background disappears unit Only Only Piece / g gram Only ％ d Example 4 21.2 814080 598 1084 648232 79.6 3 Example 5 19.4 744960 603 986.1 594618.3 79.8 3 Example 6 19 729600 602 976.8 588033.6 80.6 / Example 7 21.2 814080 593 613.6 363889 44.7 5 Comparative Example 1 19.6 752640 / / / / / Comparative Example 2 22.2 852480 598 689.9 412560.2 48.4 5 Comparative Example 3 21.6 829440 605 643.0 389007 46.9 4

[0098] It can be seen from the above Examples 4 to 7 that the pharmaceutical composition provided by the present invention can more effectively inhibit and solve the red bottom phenomenon that occurs at the bottom of the pond during the cultivation of Babylonia snails, thereby improving the success rate of the cultivation of Babylonia snails.

[0099] It can be seen from Example 4, Example 7, and Comparative Examples 1 to 3 that when the combination of Agent A, Agent B, and Agent C is used to form a pharmaceutical composition, it has an excellent synergistic effect, can significantly increase the amount of snail seedlings, the success rate of seedling cultivation, and reduce the number of days for the red background to disappear. However, it is difficult to achieve the technical effect of the present invention by arbitrarily using any two of the components in combination.

[0100] The foregoing examples are merely illustrative and are used to explain some features of the method of the present invention. The appended claims are intended to require the widest possible range that can be imagined, and the embodiments presented herein are demonstrated by the applicant's actual test results. Therefore, the applicant's intention is that the appended claims are not limited by the selection of examples that illustrate the features of the present invention. Some numerical ranges used in the claims also include sub-ranges therein, and changes in these ranges should also be interpreted as being covered by the appended claims where possible.

Claims

1. A pharmaceutical composition, characterized in that Includes dose A and dose B; The agent A includes Vibrio parahaemolyticus phage, Vibrio harveyi phage, Vibrio alginolyticus phage and Bdellovibrio phage; The B agent includes bacitracin, gramicidin, polymyxin and nisin.

2. The pharmaceutical composition according to claim 1, characterized in that The mass ratio of the Vibrio parahaemolyticus phage, the Vibrio harveyi phage, the Vibrio alginolyticus phage and the Bdellovibrio phage is 1-2:1-2:1-2:3-5.

3. The pharmaceutical composition according to claim 1, characterized in that The mass ratio of bacitracin, gramicidin, polymyxin and nisin is 1:2-4:1-3:

1.

4. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition also includes agent C; the agent C includes Bacillus subtilis, Bacillus Velez, Bacillus licheniformis, Bacillus pumilus, Bacillus coagulans, Bacillus megaterium and Bacillus circulans.

5. The pharmaceutical composition according to claim 4, characterized in that The mass ratio of the Bacillus subtilis, Bacillus Velez, Bacillus licheniformis, Bacillus pumilus, Bacillus coagulans, Bacillus megaterium and Bacillus circulans is 3-4:0.8-1.5:3-4:2-3:1.5-2:1-2:

1.

6. The pharmaceutical composition according to claim 4, characterized in that: The mass ratio of the A agent, the B agent and the C agent is 1-3:2-4:5-8.

7. The pharmaceutical composition according to claim 1, characterized in that: The pharmaceutical composition further comprises a carbon source and / or a nitrogen source.

8. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a drug for increasing the amount of Babylonia snail seedlings or the success rate of seedling cultivation.

9. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a drug for preventing and / or treating red bottom in the process of raising baby snails.

10. A method for raising seedlings of Babylonia sp., characterized in that: The pharmaceutical composition according to any one of claims 1 to 7 is used to cultivate baby cones.

Images